You suspect your patient has a bloodstream infection

You’re balancing the need to find the source with the urgency of treatment decisions and may have little to go on beyond positive blood cultures. You need to know what you’re dealing with and what options you have for therapy as quickly and safely as possible.

That’s where we come in. The Accelerate PhenoTest® BC Kit on the Accelerate Pheno® system will help you ID the organism and determine antimicrobial susceptibility results in about 7 hours directly from positive blood cultures.

You need faster results direct from positive blood cultures

Bacteremia, a frequent cause of sepsis and septic shock, continues to be a leading cause of serious illness and death despite major advances in medicine.1,2 Blood should be sterile, and when blood cultures turn positive, any delay in effective treatment increases the risk of a patient progressing to sepsis or septic shock.

This urgency — combined with increasing rates of antimicrobial resistance — mean that broad-spectrum antimicrobials are almost always the first course of treatment. And clinicians are often averse to changing that therapy until antimicrobial susceptibility results are available from the laboratory—a process that can take days.

Get faster results to optimize antimicrobial therapy and improve patient outcomes

The Accelerate Pheno® system delivers phenotypic antibiotic susceptibility results along with organism identification in about 7 hours directly from positive blood cultures — critical information to select the best drug, for the specific pathogen, at the MIC-driven dose ~40 hours faster than current methods used in most labs today.3

Hospitals around the world face similar challenges in the care of patients with bacteremia. Treatment options are limited by downward reimbursement pressures, the increasing incidence of infections from MDROs (multidrug-resistant organisms) necessitating costly isolation procedures, and delays in actionable diagnostic results.

When you get susceptibility data 1–2 days earlier than usual, you can act — you can adjust treatment and optimize the benefits of a tailored antimicrobial approach in the safest way possible for your patient.

View Outcomes Data

View Patient Cases

Bacteremia is a common and serious problem affecting 15% of critically ill patients 4

  • Bloodstream infections (BSIs) and, bacteremia specifically, are associated with threefold higher mortality4,5
  • 1 in 6 central-line associated bloodstream infections was caused by urgent or serious antibiotic-resistant threats6
  • Bacteremia has been associated with prolonged hospital stays of 2-3 weeks with $25,000 to $40,000 in additional costs7,8


1  Moreno R, et al. Incidence of sepsis in hospitalized patients. Curr Infect Dis Rep. 2006;8:346–50.
2  Goto M, et al. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013;19:501–9.
3  Banerjee R, et al. Randomized trial evaluating clinical impact of RAPid IDentification and Susceptibility testing for Gram Negative bacteremia (RAPIDS-GN), Clin Infect Dis. 2020
4 Vincent JL, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.
5 Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–90.
6 CDC Vital Signs, March 2016.
7 Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–601.
8 Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006;63:124–32.

See Results
View Outcomes Data
See the difference
View Stories